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background:  Prasugrel has proven superior anti-ischemic efficacy over clopidogrel with an increased risk of bleeding. We investigated whether 
switching from prasugrel to clopidogrel based on cytochrome (CYP) P450 2C19 genotyping is a feasible and effective method of reaching the 
therapeutic window of on-treatment platelet reactivity (OPR).
methods: CYP2C19 genotyping using direct DNA sequencing was performed in 34 patients undergoing percutaneous coronary intervention for 
acute coronary syndromes (ACS). After the administration of prasugrel 10 mg qd for 21 days, 8 patients with 2 copies of any CYP2C19*2 or *3 allele 
continued to receive prasugrel and 26 patients with at least 1 copy of the CYP2C19*1 allele were switched from prasugrel to clopidogrel. OPR was 
measured using the VerifyNow P2Y12 assay at days 21 and 35. High OPR (HOPR) was defined by P2Y12 reaction unit (PRU) ≥240; low OPR (LOPR) 
was defined by PRU <85.
results: OPR increased after genotype-directed switching from prasugrel to clopidogrel (86±59 vs 173±75, p <0.001). HOPR was higher (20.6% vs 
0%, p <0.001) and LOPR was lower (11.8% vs 52.9%, p <0.001) at day 35 than that at day 21. The number of patients who reached the therapeutic 
window of OPR (PRU 85-239) was 47.1% before and 67.6% after genotype-directed antiplatelet treatment (p=0.143, Figure)
Conclusions: CYP2C19 genotype-directed switching from prasugrel to clopidogrel decreased LOPR but increased HOPR.
 
